Menu Search
Equities

Genscript Biotech Corp

GNNSF:PKC

Genscript Biotech Corp

Actions
  • Price (USD)1.38
  • Today's Change0.00 / 0.00%
  • Shares traded2.00k
  • 1 Year change-57.00%
  • Beta--
Data delayed at least 15 minutes, as of Nov 20 2024 19:05 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Genscript Biotech Corporation is a Hong Kong-based investment holding company principally engaged in life science research and related businesses. The Company operates through four segments. Life Sciences Research Services segment includes gene and peptide synthesis, deoxyribonucleic acid (DNA) and primer synthesis, DNA sequencing, customized antibody production, protein expression and the production of stable cell lines. Preclinical Drug Development Services segment includes protein and antibody engineering, the study of in vitro drug and the study of in vivo drug. Life Sciences Research Catalog Products segment provides antibodies, recombinant proteins, equipment for protein isolation and analysis, molecular biology reagents, peptide, biochemicals and stable cell lines. Industrial Synthetic Biology Products segment is engaged in the development and production of industrial enzymes.

  • Revenue in HKD (TTM)7.86bn
  • Net income in HKD-1.38bn
  • Incorporated2015
  • Employees7.28k
  • Location
    Genscript Biotech CorpNo. 28Yongxi Road, Jiangning Science ParkNANJING ChinaCHN
  • Phone+86 2 558897288
  • Fax+86 2 558897288
  • Websitehttps://www.genscript.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.